Applications of Flufenamic Acid in Industrial Manufacturing

As a specialized manufacturer of Flufenamic Acid, we support key industries in the development of advanced finished goods through consistent quality and precise raw material integration. Our experience informs direct cooperation with pharmaceutical, veterinary, and formulation clients who require stringent compliance, well-defined process control, and reliable scale-up application data across their downstream manufacturing.

1. Nonsteroidal Anti-Inflammatory Drug (NSAID) Active Pharmaceutical Ingredient Manufacturing

Flufenamic Acid serves as a well-established nonsteroidal anti-inflammatory drug active in the pharmaceutical sector, primarily used for producing oral and topical medication for pain relief and inflammation management. API compounding hinges on accurate dosing, with GMP-compliant production strictly regulating each processing stage to safeguard therapeutic quality and purity. Our material undergoes multi-stage inspections prior to release for direct use in solid oral dosage forms, gels, and creams prepared by downstream pharmaceutical processors.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) monograph: Flufenamic Acid
• United States Pharmacopeia (USP)
• Good Manufacturing Practice (GMP) guidelines (ICH Q7)
• Registration dossiers: EMA, US FDA DMF filings

Typical usage ratio

• 5–20% w/w in solid dosage forms, adjusted for target tablet or capsule strength
• 1–3% w/w in topical gels and creams, based on formulation requirements and regional regulations

Downstream process integration

• Direct API blending during powder or granule mixing for tablets/capsules
• Dispersion into aqueous/oil base at the emulsion phase for gel/cream production
• Quality verification: Identity, purity, and residual solvents checked at the blending stage

Final product types

• Oral tablets & capsules for prescription or OTC anti-inflammatory indications
• Topical creams and gels for localized pain or inflammatory conditions
• Fixed-dose combination products with adjunct analgesics or muscle relaxants

2. Veterinary Drug Formulation

Animal health manufacturers use Flufenamic Acid as an anti-inflammatory and analgesic agent in veterinary preparations aimed at livestock, companion animals, and racing animals. Regulatory-driven batch release, careful calculation of therapeutic index for species-specific dosing, and stringent product traceability protocols define this application, integrating Flufenamic Acid into premixes or finished liquid/oral veterinary products on large-scale mixing lines.

Industry compliance standards

• Veterinary Medicinal Products Directive 2001/82/EC (EU)
• VICH GL40 Good Manufacturing Practice for Veterinary Drugs
• Pharmacopoeia Europaea: Flufenamicum for veterinary use
• FDA Center for Veterinary Medicine (CVM) guidelines, CFR Title 21 Section 520.998

Typical usage ratio

• 2–10 mg/kg animal body weight per dose, standard in oral suspensions and bolus forms
• 0.5–2% in feed premixes, varied by species and regional regulatory maximum residue limits

Downstream process integration

• Pre-dispersion in solubilized matrices before main tank blending
• Metered addition alongside excipient carriers or liquid phase dispersants
• QC: Microbial testing and uniformity analysis after active incorporation

Final product types

• Oral suspensions for equine, bovine, or canine administration
• Feed additive premixes for ruminants and swine
• Veterinary boluses and pastes with controlled-release characteristics

3. Analytical Reference Standard Production for Quality Control Laboratories

High-purity Flufenamic Acid acts as an essential reference substance in pharmaceutical quality control and analytical chemistry laboratories, supporting identity verification, calibration, and trace impurity analysis for regulatory submissions and batch release validation. Our material’s traceable documentation, batch homogeneity verification, and multi-method compatibility enable its integration at the method calibration and system suitability stages across accredited facilities.

Industry compliance standards

• USP Reference Standards (RS) program
• European Pharmacopoeia Reference Standards
• ISO/IEC 17025 Laboratory Accreditation
• WHO Technical Report Series for pharmaceutical reference material

Typical usage ratio

• 50–100 mg/vial for standard solution preparation
• 0.1–1% calibration spike in analytical method validation and recovery studies

Downstream process integration

• Direct weighing and dissolution for HPLC/GC calibration curve setup
• Spiking blank or sample matrices for comparative analysis and system suitability testing
• Aliquoting into single-use or bulk-labeled vials under validated conditions

Final product types

• Certified analytical reference vials for QC/QA use in pharmaceutical companies
• Calibration standards for regulatory inspections and batch release testing
• System suitability test mixtures used in analytical method development

4. Pharmaceutical Formulation Research and Development

Formulation and drug delivery research laboratories utilize Flufenamic Acid in technical-grade batches to develop new dosage forms, alternative delivery routes, and bioenhanced solutions. These R&D applications require precise documentation for compound traceability, analytical comparability data, and adjustment of incorporation technique for prototyped forms such as nanoparticles, micelles, or biodegradable matrices during pilot-scale design and preclinical evaluation.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• ICH Q8 Pharmaceutical Development
• EMA/FDA guidelines for Investigational Medicinal Products (IMPs)
• Pharmacopoeia monograph reference for identity and purity testing

Typical usage ratio

• Varies widely: 0.1–10% depending on the experimental formulation type and release characteristics targeted
• Initial screens: 1% w/w for solid dispersions; can exceed 5% for high-dose alternative delivery systems

Downstream process integration

• Solubilization in preformulation studies prior to blend adjustment
• Incorporation into melt extrusion or solvent casting lines for prototype creation
• Post-formulation purity re-confirmation by HPLC/MS to confirm compound stability

Final product types

• R&D prototype tablets, capsules, and films for preclinical testing
• Microparticles and nanocarriers for enhanced delivery research
• Investigational samples for pharmacokinetic and toxicological screening